Abstract:
Elan Corporation announced today that its drug delivery business unit, NanoSystems, and Bristol-Myers Squibb have signed a license agreement for NanoCrystal(TM) technology. This license will provide Bristol-Myers Squibb with access to NanoCrystal technology and the right to develop and commercialize products incorporating this technology.